Across TCGA pan-cancer cohorts, ARID2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARID2 data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARID2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARID2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where ARID2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.962	0.672	.003	28	view →
HNSC	OS	Median	All	0.806	0.895	.010	17	view →
CCRCC	DFS	Quartile	II,III,IV	0.296	0.842	.007	15	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ARID2 tumor-vs-normal RNA expression · all ARID2 data types